Literature DB >> 21350020

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.

Ana María Martín-Moreno1, David Reigada, Belén G Ramírez, R Mechoulam, Nadia Innamorato, Antonio Cuadrado, María L de Ceballos.   

Abstract

Microglial activation is an invariant feature of Alzheimer's disease (AD). It is noteworthy that cannabinoids are neuroprotective by preventing β-amyloid (Aβ)-induced microglial activation both in vitro and in vivo. On the other hand, the phytocannabinoid cannabidiol (CBD) has shown anti-inflammatory properties in different paradigms. In the present study, we compared the effects of CBD with those of other cannabinoids on microglial cell functions in vitro and on learning behavior and cytokine expression after Aβ intraventricular administration to mice. CBD, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo-[1,2,3-d,e]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone [WIN 55,212-2 (WIN)], a mixed CB(1)/CB(2) agonist, and 1,1-dimethylbutyl-1-deoxy-Δ(9)-tetrahydrocannabinol [JWH-133 (JWH)], a CB(2)-selective agonist, concentration-dependently decreased ATP-induced (400 μM) increase in intracellular calcium ([Ca(2+)](i)) in cultured N13 microglial cells and in rat primary microglia. In contrast, 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol [HU-308 (HU)], another CB(2) agonist, was without effect. Cannabinoid and adenosine A(2A) receptors may be involved in the CBD action. CBD- and WIN-promoted primary microglia migration was blocked by CB(1) and/or CB(2) antagonists. JWH and HU-induced migration was blocked by a CB(2) antagonist only. All of the cannabinoids decreased lipopolysaccharide-induced nitrite generation, which was insensitive to cannabinoid antagonism. Finally, both CBD and WIN, after subchronic administration for 3 weeks, were able to prevent learning of a spatial navigation task and cytokine gene expression in β-amyloid-injected mice. In summary, CBD is able to modulate microglial cell function in vitro and induce beneficial effects in an in vivo model of AD. Given that CBD lacks psychoactivity, it may represent a novel therapeutic approach for this neurological disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350020      PMCID: PMC3102548          DOI: 10.1124/mol.111.071290

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Activation of mouse microglial cells affects P2 receptor signaling.

Authors:  T Möller; O Kann; A Verkhratsky; H Kettenmann
Journal:  Brain Res       Date:  2000-01-17       Impact factor: 3.252

2.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

3.  Purinergic receptors activating rapid intracellular Ca increases in microglia.

Authors:  Alan R Light; Ying Wu; Ronald W Hughen; Peter B Guthrie
Journal:  Neuron Glia Biol       Date:  2006-05

4.  Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells.

Authors:  You-Hong Cui; Yingying Le; Wanghua Gong; Paul Proost; Jo Van Damme; William J Murphy; Ji Ming Wang
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; J Millan; J M Derocq; P Casellas; C Congy; D Oustric; M Sarran; M Bouaboula; B Calandra; M Portier; D Shire; J C Brelière; G L Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

6.  Monokine production by microglial cell clones.

Authors:  M Righi; L Mori; G De Libero; M Sironi; A Biondi; A Mantovani; S D Donini; P Ricciardi-Castagnoli
Journal:  Eur J Immunol       Date:  1989-08       Impact factor: 5.532

Review 7.  Acute neuronal injury, excitotoxicity, and the endocannabinoid system.

Authors:  Mario van der Stelt; Wouter B Veldhuis; Mauro Maccarrone; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Vincenzo Di Marzo; Johannes F G Vliegenthart
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

8.  Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells.

Authors:  Alison J Drysdale; Duncan Ryan; Roger G Pertwee; Bettina Platt
Journal:  Neuropharmacology       Date:  2005-12-28       Impact factor: 5.250

9.  CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes.

Authors:  Susana Mato; Elena Alberdi; Catherine Ledent; Masahiko Watanabe; Carlos Matute
Journal:  Glia       Date:  2009-02       Impact factor: 7.452

10.  Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.

Authors:  Fabrizio Facchinetti; Elda Del Giudice; Sara Furegato; Marzla Passarotto; Alberta Leon
Journal:  Glia       Date:  2003-01-15       Impact factor: 7.452

View more
  84 in total

1.  Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli.

Authors:  Ananda Chowdhury; Rentian Feng; Qin Tong; Yuxun Zhang; Xiang-Qun Xie
Journal:  Protein Expr Purif       Date:  2012-03-03       Impact factor: 1.650

Review 2.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 5.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 6.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

7.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

8.  A high-quality reference genome of wild Cannabis sativa.

Authors:  Shan Gao; Baishi Wang; Shanshan Xie; Xiaoyu Xu; Jin Zhang; Li Pei; Yongyi Yu; Weifei Yang; Ying Zhang
Journal:  Hortic Res       Date:  2020-05-02       Impact factor: 6.793

9.  Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets.

Authors:  Håvard T Garberg; Marianne U Huun; Javier Escobar; Jose Martinez-Orgado; Else-Marit Løberg; Rønnaug Solberg; Ola Didrik Saugstad
Journal:  Pediatr Res       Date:  2016-07-21       Impact factor: 3.756

10.  Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.

Authors:  David Cheng; Jac Kee Low; Warren Logge; Brett Garner; Tim Karl
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.